Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.67 - $7.28 $467,934 - $729,456
100,200 Added 161.35%
162,300 $757,000
Q1 2024

May 14, 2024

BUY
$7.03 - $11.07 $436,563 - $687,447
62,100 New
62,100 $460,000
Q3 2023

Nov 13, 2023

BUY
$6.92 - $9.31 $692 - $931
100 Added 0.53%
18,800 $146,000
Q2 2023

Aug 11, 2023

BUY
$6.36 - $11.47 $118,932 - $214,489
18,700 New
18,700 $153,000
Q2 2022

Aug 12, 2022

SELL
$9.99 - $21.35 $253,746 - $542,290
-25,400 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$14.08 - $27.63 $66,176 - $129,861
-4,700 Reduced 15.61%
25,400 $483,000
Q2 2021

Aug 13, 2021

BUY
$31.29 - $56.64 $941,829 - $1.7 Million
30,100 New
30,100 $1.71 Million
Q1 2021

May 14, 2021

SELL
$39.71 - $90.58 $1.2 Million - $2.74 Million
-30,200 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$27.07 - $84.35 $817,514 - $2.55 Million
30,200 New
30,200 $2.12 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $239M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Peak6 Investments LLC Portfolio

Follow Peak6 Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak6 Investments LLC with notifications on news.